Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Rituximab
100%
High-dose Therapy
100%
Aggressive non-Hodgkin Lymphoma
100%
Hematopoietic Cell Transplantation
75%
Survival Rate
50%
B-cell Lymphoma
50%
Overall Survival Rate
50%
Event-free Survival
50%
Immune Reconstitution
25%
Neutropenia
25%
Relapsed or Refractory
25%
Safety Profile
25%
Lymphocyte Subsets
25%
Diffuse Large Cell
25%
Immunoglobulin
25%
Diffuse Large B-cell Lymphoma (DLBCL)
25%
Large B-cell Lymphoma
25%
Phase II Trial
25%
Immunoglobulin G
25%
Serious Infection
25%
Antibody Titer
25%
Lymphocyte Activation
25%
Response to Vaccination
25%
Independent Activity
25%
Patient Subtypes
25%
Autologous Graft
25%
Pneumococcus
25%
Mantle Cell
25%
G-levels
25%
B Cell Recovery
25%
Medicine and Dentistry
Cell Transplantation
100%
Drug Megadose
100%
Non-Hodgkin Lymphoma
100%
Rituximab
100%
Hematopoietic Cell
100%
Survival Rate
80%
Overall Survival
40%
Event Free Survival
40%
B-Cell Lymphoma
40%
Large-Cell Lymphoma
40%
Infection
20%
B Cell
20%
Neutropenia
20%
Infusion
20%
Prospective Study
20%
Lymphocyte Subpopulation
20%
Large Cell
20%
Immune Reconstitution
20%
Immunoglobulin G
20%
Streptococcus Pneumonia
20%
Immunology and Microbiology
Hematopoietic Cell
100%
Drug Megadose
100%
Rituximab
100%
Cell Transplantation
100%
Survival Rate
80%
B Cell
60%
Overall Survival
40%
Lymphoma Cell
40%
Event Free Survival
40%
Immune Reconstitution
20%
Lymphocyte Subpopulation
20%
Immunoglobulin G
20%
Antibody Titer
20%
Streptococcus Pneumonia
20%
Immunoglobulin
20%
Infection
20%